Remission after Rituximab Therapy in Refractory Myasthenia Gravis

Myasthenia gravis (MG) is estimated to be refractory in approximately 10% of patients with generalized MG. A 35-year-old man was diagnosed as generalized MG with thymoma. Despite aggressive immunotherapies, his myasthenic symptoms relapsed five times within one year. We therefore administered rituximab for treating the refractory MG, and this resulted in remission. There are few reports on treating MG with rituximab, but this case suggests that rituximab can be an effective treatment option for refractory MG.